Valley National Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Valley National Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88K	Hold	85	–	–	﹤0.01%	765
2026 Q1	$2K	Hold	85	–	–	﹤0.01%	781
2025 Q4	$2K	Buy	+85	New	+$2.09K	﹤0.01%	805
2025 Q3	–	Sell	-85	Closed	-$1K	–	894
2025 Q2	$1K	Hold	85	–	–	﹤0.01%	800
2025 Q1	$1K	Hold	85	–	–	﹤0.01%	801
2024 Q4	$1K	Hold	85	–	–	﹤0.01%	762
2024 Q3	$1K	Hold	85	–	–	﹤0.01%	725
2024 Q2	$1K	Hold	85	–	–	﹤0.01%	1133
2024 Q1	$1K	Buy	+85	New	+$1.07K	﹤0.01%	1180
2023 Q4	–	Sell	-85	Closed	-$1K	–	1273
2023 Q3	$1K	Hold	85	–	–	﹤0.01%	1019
2023 Q2	$1K	Hold	85	–	–	﹤0.01%	939
2023 Q1	$1K	Hold	85	–	–	﹤0.01%	853
2022 Q4	$0	Hold	85	–	–	﹤0.01%	975
2022 Q3	$1K	Sell	85 -302	-78%	-$2.67K	﹤0.01%	877
2022 Q2	$3K	Hold	387	–	–	﹤0.01%	735
2022 Q1	$4K	Hold	387	–	–	﹤0.01%	733
2021 Q4	$3K	Hold	387	–	–	﹤0.01%	758
2021 Q3	$4K	Hold	387	–	–	﹤0.01%	706
2021 Q2	$4K	Hold	387	–	–	﹤0.01%	712
2021 Q1	$4K	Hold	387	–	–	﹤0.01%	666
2020 Q4	$4K	Hold	387	–	–	﹤0.01%	641
2020 Q3	$3K	Hold	387	–	–	﹤0.01%	633
2020 Q2	$5K	Sell	387 -110	-22%	-$1.24K	﹤0.01%	567
2020 Q1	$4K	Buy	497 +10	+2%	+$102	﹤0.01%	586
2019 Q4	$5K	Hold	487	–	–	﹤0.01%	612
2019 Q3	$3K	Buy	487 +100	+26%	+$766	﹤0.01%	651
2019 Q2	$4K	Hold	387	–	–	﹤0.01%	581
2019 Q1	$6K	Hold	387	–	–	﹤0.01%	547
2018 Q4	$6K	Sell	387 -352	-48%	-$7.22K	﹤0.01%	510
2018 Q3	$16K	Buy	739 +352	+91%	+$8.17K	0.01%	387
2018 Q2	$9K	Hold	387	–	–	﹤0.01%	430
2018 Q1	$7K	Hold	387	–	–	﹤0.01%	439
2017 Q4	$7K	Hold	387	–	–	﹤0.01%	451
2017 Q3	$7K	Hold	387	–	–	﹤0.01%	449
2017 Q2	$13K	Hold	387	–	–	﹤0.01%	380
2017 Q1	$12K	Buy	387 +302	+355%	+$10.3K	﹤0.01%	385
2016 Q4	$3K	Sell	85 -36	-30%	-$1.44K	﹤0.01%	541
2016 Q3	$6K	Hold	121	–	–	﹤0.01%	441
2016 Q2	$6K	Hold	121	–	–	﹤0.01%	441
2016 Q1	$6K	Buy	121 +52	+75%	+$3.05K	﹤0.01%	427
2015 Q4	$5K	Hold	69	–	–	﹤0.01%	449
2015 Q3	$4K	Hold	69	–	–	﹤0.01%	470
2015 Q2	$4K	Hold	69	–	–	﹤0.01%	476
2015 Q1	$4K	Buy	69 +33	+92%	+$1.92K	﹤0.01%	456
2014 Q4	$1K	Buy	+36	New	+$2.01K	﹤0.01%	408

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Valley National Advisers's TEVA Position: Q2 2026 in Review

Valley National Advisers held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 85 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Valley National Advisers first reported a position in TEVA in Q4 2014 and has held it in 45 quarters since. The position peaked at $16K in Q3 2018. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Valley National Advisers held 85 shares of Teva Pharmaceuticals worth $2.88K as of Q2 2026.
Valley National Advisers left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #765 holding.
Valley National Advisers first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
Valley National Advisers's Teva Pharmaceuticals position peaked at $16K in Q3 2018.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.